Terms: = Ovarian cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Clinical Outcome
26 results:
1. Machine learning developed a pi3k/Akt pathway-related signature for predicting prognosis and drug sensitivity in ovarian cancer.
Han X; Yang L; Tian H; Ji Y
Aging (Albany NY); 2023 Oct; 15(20):11162-11183. PubMed ID: 37851341
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer.
Schnack TH; Oliveira DNP; Christiansen AP; Høgdall C; Høgdall E
Cancer Genet; 2023 Nov; 278-279():9-16. PubMed ID: 37567101
[TBL] [Abstract] [Full Text] [Related]
3. PTEN Deficiency in Tubo-ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification.
Zhang X; Wang A; Han L; Liang B; Allard G; Diver E; Howitt BE
Mod Pathol; 2023 May; 36(5):100106. PubMed ID: 36805789
[TBL] [Abstract] [Full Text] [Related]
4. Modulation of intracellular kinase signaling to improve TIL stemness and function for adoptive cell therapy.
Feng H; Qiu L; Shi Z; Sheng Y; Zhao P; Zhou D; Li F; Yu H; You Y; Wang H; Li M; Zhu S; Du Y; Cui J; Sun J; Liu Y; Jiang H; Wu X
Cancer Med; 2023 Feb; 12(3):3313-3327. PubMed ID: 36028997
[TBL] [Abstract] [Full Text] [Related]
5. clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma.
Kobayashi Kato M; Asami Y; Takayanagi D; Matsuda M; Shimada Y; Hiranuma K; Kuno I; Komatsu M; Hamamoto R; Matsumoto K; Ishikawa M; Kohno T; Kato T; Shiraishi K; Yoshida H
Cancer Sci; 2022 May; 113(5):1712-1721. PubMed ID: 35278272
[TBL] [Abstract] [Full Text] [Related]
6. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome.
Hollis RL; Thomson JP; Stanley B; Churchman M; Meynert AM; Rye T; Bartos C; Iida Y; Croy I; Mackean M; Nussey F; Okamoto A; Semple CA; Gourley C; Herrington CS
Nat Commun; 2020 Oct; 11(1):4995. PubMed ID: 33020491
[TBL] [Abstract] [Full Text] [Related]
7. Clear cell carcinoma of the ovary: a clinical and molecular perspective.
Iida Y; Okamoto A; Hollis RL; Gourley C; Herrington CS
Int J Gynecol Cancer; 2021 Apr; 31(4):605-616. PubMed ID: 32948640
[TBL] [Abstract] [Full Text] [Related]
8. Corded and Hyalinized Endometrioid Adenocarcinoma (CHEC) of the Uterine Corpus are Characterized by CTNNB1 Mutations and Can Show Adverse clinical outcomes.
Ladwig NR; Umetsu SE; Zaloudek C; Rabban J; Garg K
Int J Gynecol Pathol; 2021 Mar; 40(2):103-115. PubMed ID: 32909971
[TBL] [Abstract] [Full Text] [Related]
9. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
[TBL] [Abstract] [Full Text] [Related]
10. Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
Nan X; Wang J; Cheng H; Yin Z; Sheng J; Qiu B; Lau CC; Yustein JT; Zhao H; Wong STC
Cancer Lett; 2020 Jan; 469():195-206. PubMed ID: 31672491
[TBL] [Abstract] [Full Text] [Related]
11. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-pi3k/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract] [Full Text] [Related]
12. TLR5/7-mediated pi3k activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression.
Park GB; Kim D
Oncol Rep; 2017 Nov; 38(5):3167-3176. PubMed ID: 28901470
[TBL] [Abstract] [Full Text] [Related]
13. PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.
Gadducci A; Guerrieri ME
Crit Rev Oncol Hematol; 2017 Jun; 114():153-165. PubMed ID: 28477743
[TBL] [Abstract] [Full Text] [Related]
14. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract] [Full Text] [Related]
15. In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.
Yu Y; Hall T; Eathiraj S; Wick MJ; Schwartz B; Abbadessa G
Anticancer Drugs; 2017 Jun; 28(5):503-513. PubMed ID: 28240679
[TBL] [Abstract] [Full Text] [Related]
16. Amplification of USP13 drives ovarian cancer metabolism.
Han C; Yang L; Choi HH; Baddour J; Achreja A; Liu Y; Li Y; Li J; Wan G; Huang C; Ji G; Zhang X; Nagrath D; Lu X
Nat Commun; 2016 Nov; 7():13525. PubMed ID: 27892457
[TBL] [Abstract] [Full Text] [Related]
17. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
[TBL] [Abstract] [Full Text] [Related]
18. Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
Uehara Y; Oda K; Ikeda Y; Koso T; Tsuji S; Yamamoto S; Asada K; Sone K; Kurikawa R; Makii C; Hagiwara O; Tanikawa M; Maeda D; Hasegawa K; Nakagawa S; Wada-Hiraike O; Kawana K; Fukayama M; Fujiwara K; Yano T; Osuga Y; Fujii T; Aburatani H
PLoS One; 2015; 10(6):e0128066. PubMed ID: 26043110
[TBL] [Abstract] [Full Text] [Related]
19. Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous ovarian cancer and Sensitivity to pi3k Inhibition.
Davis SJ; Sheppard KE; Anglesio MS; George J; Traficante N; Fereday S; Intermaggio MP; Menon U; Gentry-Maharaj A; Lubinski J; Gronwald J; Pearce CL; Pike MC; Wu A; Kommoss S; Pfisterer J; du Bois A; Hilpert F; Ramus SJ; Bowtell DD; Huntsman DG; Pearson RB; Simpson KJ; Campbell IG; Gorringe KL
Mol Cancer Ther; 2015 Jun; 14(6):1495-503. PubMed ID: 25852062
[TBL] [Abstract] [Full Text] [Related]
20. Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.
Coenegrachts L; Garcia-Dios DA; Depreeuw J; Santacana M; Gatius S; Zikan M; Moerman P; Verbist L; Lambrechts D; Matias-Guiu X; Amant F
Virchows Arch; 2015 Apr; 466(4):415-22. PubMed ID: 25677978
[TBL] [Abstract] [Full Text] [Related]
[Next]
